(photo: )

Eli Lilly grows migraine portfolio with $960m CoLucid acquisition

Eli Lilly is enhancing its pain management portfolio for migraine with the $960 million acquisition of CoLucid Pharmaceuticals.




  •  (photo: )

    Pharmaceutical growth continues to set technology pace

    While food and beverage remain the largest sectors in terms of packaging machinery needs, no market can keep pace with the pharmaceutical growth forecast through 2020, according to the 2016 State of the Industry US Packaging Machinery Report.




 (photo: )

ABPI welcomes Prime Minister’s speech negotiating Brexit

The UK pharmaceutical industry trade body, the Association of the British Pharmaceutical Industry (ABPI), has welcomed the Prime Minister’s speech on the Government’s negotiating objectives for exiting the EU.

 (photo: )

EMA revising guideline on first-in-human clinical trials

The European Medicines Agency (EMA), in cooperation with the European Commission and the Member States of the European Union, is proposing changes to its existing guideline on first-in-human clinical trials, to further improve the safety of trial participants.


 (photo: )

Yorkshire pharma startup ships first medicines to Iraq

The first consignment of British manufactured medicines has been exported to Iraq by a new Yorkshire pharmaceuticals wholesaler and distributor set up to give Iraqi people access to high-quality treatments.

 (photo: )

TraceLink raises $51m to accelerate pharma track & trace

TraceLink, a track and trace network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, has raised $51.5 million in Series C financing.


 (photo: )

FDA approves Teva’s anti-abuse painkiller

The US Food and Drug Administration has approved Teva Pharmaceutical’s Vantrelatm ER, an opioid formulated with its proprietary abuse deterrence technology.

 (photo: )

Sanofi’s diabetes treatment gains approval in Europe

The European Commission has granted marketing authorisation in Europe for Sanofi’s treatment for adults with type 2 diabetes.